VivoSeq
Metabolic & Endocrine

Hypoparathyroidism

33

Pipeline Programs↗

14

Active Trials↗

14

Companies Involved↗

Hypoparathyroidism is a moderately active landscape with 33 programs across 14 companies. The most active players are Extend Biosciences Inc., AstraZeneca, Otsuka. 4 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

81/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Extend Biosciences Inc.

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2Otsuka logo

Otsuka

1 program

Phase 2A

Almaject

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Roche logo

Roche

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

35 of 38 classified programs — the dominant modality here.

8%ALL OTHERSPeptide25%Radiopharmaceutical13%

Small molecule leads; the ring shows all 38 classified programs, each share of the total. Modality classified for 98% of 42 pipeline programs.

Analysis

Trial Status

46

clinical trials

Completed22 · 48%
Recruiting9 · 20%
Terminated4 · 9%
Unknown status4 · 9%
Active, not recruiting4 · 9%
Withdrawn1 · 2%
Other2 · 4%

Clinical Trials

Trial Activity

46 trials

Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism
Recruiting·PPeking Union Medical College Hospital·Phase 1·NCT07197450·6 enrolled
Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism
Recruiting·—·Phase 4·NCT07034677·24 enrolled
PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery"
Recruiting·—·N/A·NCT07491601·336 enrolled
Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults
Recruiting·AAmorphical Ltd.·Phase 2·NCT06547151·81 enrolled
Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy
Recruiting·UUniversity Hospital, Brest·Phase 3·NCT04785443·242 enrolled
A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism
Recruiting·EExtend Biosciences Inc.·Phase 2·NCT06988670·35 enrolled
Effect of Theophylline in Pseudohypoparathyroidism
Recruiting·MMassachusetts General Hospital·Phase 4·NCT03718403·100 enrolled
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
Recruiting·—·Phase 1/2·NCT06961071·3 enrolled
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism
Recruiting·MMBX Biosciences·Phase 3·NCT07699471·160 enrolled
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
Active, not recruiting·MMBX Biosciences·Phase 2·NCT06531941·60 enrolled
Theophylline Treatment for Pseudohypoparathyroidism
Active, not recruiting·VVanderbilt University Medical Center·Phase 2·NCT03029429·29 enrolled
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
Active, not recruiting·VVanderbilt University Medical Center·Phase 2·NCT04551170·34 enrolled
PaTHway: TransCon PTH in Hypoparathyroidism
Active, not recruiting·Ascendis Pharma logoAscendis Pharma·Phase 3·NCT04820231·84 enrolled
Theophylline for Treatment of Pseudohypoparathyroidism
Enrolling by invitation·—·Phase 2·NCT04240821·34 enrolled
Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism
Completed·Takeda logoTakeda·Phase 1·NCT02781844·34 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)